千红制药：收到江苏证监局对公司股东出具警示函

Core Viewpoint - Qianhong Pharmaceutical (002550.SZ) received a warning letter from the Jiangsu Regulatory Bureau of the China Securities Regulatory Commission regarding a violation of disclosure regulations related to shareholding changes by Wang Ke [1] Summary by Relevant Sections - Incident Details - On June 11, 2025, Wang Ke increased his stake in Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. by acquiring 9.6 million shares through block trading, amounting to 84.096 million yuan [1] - Following this transaction, the combined shareholding percentage of Wang Ke and his concerted action partner Wang Yaofang rose from 24.91% to 25.66% [1] - Regulatory Findings - Wang Ke failed to timely disclose the increase in shareholding when it reached the 25% threshold and only reported it on June 20, 2025, through a detailed equity change report and a notice regarding the change in concerted action rights [1] - This behavior was found to violate Article 13, Paragraphs 1 and 2 of the "Measures for the Administration of the Acquisition of Listed Companies" (CSRC Order No. 227) [1] - Consequences - The Jiangsu Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure, which will be recorded in the securities and futures market integrity file [1] - Wang Ke is required to reflect on this incident, enhance his understanding of securities laws and regulations, and submit a written report to the bureau within 10 working days from the receipt of the decision [1]